➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Colorcon
Dow
Baxter
Mallinckrodt

Last Updated: September 26, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR COLCHICINE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for colchicine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000577 Asthma Clinical Research Network (ACRN) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1993-09-01 This study will establish a network of interactive asthma clinical research groups to evaluate current therapies, new therapies, and management strategies for adult asthma.
NCT00004368 Phase I Study of Colchicine Therapy in Childhood Hepatic Cirrhosis Unknown status Children's Hospital Colorado Phase 1 1990-05-01 OBJECTIVES: I. Investigate the efficacy and safety of colchicine therapy in improving hepatic function and reducing hepatic fibrosis (scarring) in children with hepatic cirrhosis.
NCT00004368 Phase I Study of Colchicine Therapy in Childhood Hepatic Cirrhosis Unknown status National Center for Research Resources (NCRR) Phase 1 1990-05-01 OBJECTIVES: I. Investigate the efficacy and safety of colchicine therapy in improving hepatic function and reducing hepatic fibrosis (scarring) in children with hepatic cirrhosis.
NCT00004748 Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis Completed Tufts Medical Center Phase 3 1989-11-01 OBJECTIVES: I. Compare the efficacy of low-dose oral pulse methotrexate (MTX) and ursodiol versus colchicine and ursodiol in patients with primary biliary cirrhosis (PBC). II. Determine the optimum dose and duration of MTX treatment. III. Investigate the role of fibrogenic cytokines (FC) in PBC pathogenesis and the effect of treatment on FC production.
NCT00004748 Low-Dose Oral Methotrexate Versus Colchicine for Primary Biliary Cirrhosis Completed National Center for Research Resources (NCRR) Phase 3 1989-11-01 OBJECTIVES: I. Compare the efficacy of low-dose oral pulse methotrexate (MTX) and ursodiol versus colchicine and ursodiol in patients with primary biliary cirrhosis (PBC). II. Determine the optimum dose and duration of MTX treatment. III. Investigate the role of fibrogenic cytokines (FC) in PBC pathogenesis and the effect of treatment on FC production.
NCT00047489 Study of ABT-751 in Patients With Refractory Hematologic Malignancies Completed M.D. Anderson Cancer Center Phase 1 2002-12-01 ABT-751 is a new antitumor drug that that interferes with cell division. The goal of this clinical research study is to find the highest safe dose of ABT-751 that can be given as a treatment for refractory hematologic malignancies. The safety and side effects of ABT-751 will also be studied.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for colchicine

Condition Name

Condition Name for colchicine
Intervention Trials
Gout 20
Pharmacokinetics 13
Atrial Fibrillation 10
Healthy 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for colchicine
Intervention Trials
Gout 23
Atrial Fibrillation 13
Myocardial Infarction 12
Infarction 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for colchicine

Trials by Country

Trials by Country for colchicine
Location Trials
United States 325
Canada 23
China 15
France 13
Italy 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for colchicine
Location Trials
California 19
New York 18
North Dakota 15
Florida 15
Texas 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for colchicine

Clinical Trial Phase

Clinical Trial Phase for colchicine
Clinical Trial Phase Trials
Phase 4 28
Phase 3 39
Phase 2/Phase 3 6
[disabled in preview] 77
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for colchicine
Clinical Trial Phase Trials
Completed 74
Not yet recruiting 38
Recruiting 28
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for colchicine

Sponsor Name

Sponsor Name for colchicine
Sponsor Trials
Mutual Pharmaceutical Company, Inc. 20
Takeda 7
Novartis Pharmaceuticals 7
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for colchicine
Sponsor Trials
Other 162
Industry 58
NIH 12
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Harvard Business School
Baxter
Merck
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.